Differential blood and mucosal immune responses against an HIV-1 vaccine administered via inguinal or deltoid injection e88621

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Yang, Otto O ^a,b   Ibarrondo, F Javier ^a   Price, Charles ^a   Hultin, Lance E ^a   Elliott, Julie ^a   Hultin, Patricia M ^a   Shih, Roger ^a   Hausner, Mary Ann ^a   Ng, Hwee L ^a   Hoffman, Jennifer ^a   Jamieson, Beth D ^a   Anton, Peter A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b AIDS HEALTHCARE FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; ALVAC-HIV VCP205 VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; RECOMBINANT VACCINE;

ADULT; ANTIBODY DETECTION; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DELTOID MUSCLE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; INGUINAL REGION; INJECTION SITE ERYTHEMA; INJECTION SITE REACTION; INJECTION SITE SWELLING; MALE; MUCOSAL IMMUNITY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VACCINATION; BLOOD; CANARYPOX VIRUS; CLINICAL TRIAL; CYTOLOGY; IMMUNOLOGY; INGUINAL CANAL; MIDDLE AGED; MONONUCLEAR CELL; MUCOSA; PATHOLOGY; VIROLOGY;

ADULT; AIDS VACCINES; CANARYPOX VIRUS; CD8-POSITIVE T-LYMPHOCYTES; DELTOID MUSCLE; DOUBLE-BLIND METHOD; FEMALE; HIV ANTIBODIES; HIV-1; HUMANS; IMMUNITY, HUMORAL; IMMUNITY, MUCOSAL; INGUINAL CANAL; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUCOUS MEMBRANE; VACCINES, SYNTHETIC;

EID: 84897804953     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088621     Document Type: Article

References (29)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. NEJMoa0908492 [pii];10.1056/NEJMoa0908492 [doi].
2. McElrath MJ, Haynes BF (2010) Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33: 542-554. S1074-7613(10)00354-7 [pii];10.1016/j.immuni.2010.09.011 [doi].
3. Shacklett BL, Anton PA (2010) HIV Infection and Gut Mucosal Immune Function: Updates on Pathogenesis with Implications for Management and Intervention. Curr Infect Dis Rep 12: 19-27.
4. Veazey RS, DeMaria M, Chalifoux LV, Shvetz DE, Pauley DR, et al (1998) Gastrointestinal tract as a major site of CD4 + T cell depletion and viral replication in SIV infection. Science 280: 427-431. (Pubitemid 28208163)
5. Belyakov IM, Isakov D, Zhu Q, Dzutsev A, Berzofsky JA (2007) A novel functional CTL avidity/activity compartmentalization to the site of mucosal immunization contributes to protection of macaques against simian/human immunodeficiency viral depletion of mucosal CD4+ T cells. J Immunol 178: 7211-7221. 178/11/7211 [pii].
6. Perreau M, Welles HC, Harari A, Hall O, Martin R, et al (2011) DNA/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa. J Virol 85: 9854-9862. JVI.00788-11 [pii];10.1128/JVI.00788-11 [doi].
7. Ferre AL, Lemongello D, Hunt PW, Morris MM, Garcia JC, et al (2010) Immunodominant HIV-specific CD8+ T-cell responses are common to blood and gastrointestinal mucosa, and Gag-specific responses dominate in rectal mucosa of HIV controllers. J Virol 84: 10354-10365. JVI.00803-10 [pii];10.1128/JVI.00803- 10 [doi].
8. Hird TR, Grassly NC (2012) Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge. PLoS Pathog 8: e1002599. 10.1371/journal.ppat.1002599 [doi];PPATHOGENS-D-12-00038 [pii].
9. Belyakov IM, Ahlers JD (2009) What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J Immunol 183: 6883-6892. 183/11/6883 [pii];10.4049/jimmunol.0901466 [doi].
10. Bolton DL, Song K, Wilson RL, Kozlowski PA, Tomaras GD, et al (2012) Comparison of systemic and mucosal vaccination: impact on intravenous and rectal SIV challenge. Mucosal Immunol 5: 41-52. mi201145 [pii];10.1038/mi.2011.45 [doi].
11. Lehner T (2003) Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 21 Suppl 2: S68-S76.
12. Russell ND, Graham BS, Keefer MC, McElrath MJ, Self SG, et al (2007) Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 44: 203-212. 10.1097/01.qai.0000248356.48501.ff [doi]. (Pubitemid 46292224)
13. Ackers ML, Parekh B, Evans TG, Berman P, Phillips S, et al (2003) Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J Infect Dis 187: 879-886. JID20717 [pii];10.1086/368169 [doi].
14. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, et al (2001) CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 107: 1303-1310. (Pubitemid 32494547)
15. Anton PA, Elliott J, Poles MA, McGowan IM, Matud J, et al (2000) Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS 14: 1761-1765.
16. Anton PA, Poles MA, Elliott J, Mao SH, McGowan I et al (2001) Sensitive and reproducible quantitation of mucosal HIV-1 RNA and DNA viral burden in patients with detectable and undetectable plasma viral HIV-1 RNA using endoscopic biopsies. J Virol Methods 95: 65-79. S0166093401002956 [pii].
17. Shacklett BL, Yang O, Hausner MA, Elliott J, Hultin L, et al (2003) Optimization of methods to assess human mucosal T-cell responses to HIV infection. Journal of Immunological Methods 279: 17-31. (Pubitemid 37297487)
18. Kozlowski PA, Lynch RM, Patterson RR, Cu-Uvin S, Flanigan TP, Neutra MR (2000) Modified wick method using Weck-Cel sponges for collection of human rectal secretions and analysis of mucosal HIV antibody. J Acquir Immune Defic Syndr 24: 297-309.
19. Ellenberger D, Otten RA, Li B, Aidoo M, Rodriguez IV, et al (2006) HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 352: 216-225. S0042-6822(06)00240-6 [pii];10.1016/j.virol.2006.04.005 [doi].
20. Anton PA, Ibarrondo FJ, Boscardin WJ, Zhou Y, Schwartz EJ, et al (2008) Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments. Vaccine 26: 4617-4623. S0264-410X(08)00611-7 [pii];10.1016/j.vaccine.2008.05.084 [doi].
21. Jamieson BD, Ibarrondo FJ, Wong JT, Hausner MA, Ng HL, et al (2006) Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response". Vaccine 24: 3426-3431.
22. Ibarrondo FJ, Anton PA, Fuerst M, Ng HL, Wong JT, et al (2005) Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol 79: 4289-4297. (Pubitemid 40388366)
23. Jones N, Agrawal D, Elrefaei M, Hanson A, Novitsky V, et al (2003) Evaluation of antigen-specific responses using in vitro enriched T cells. J Immunol Methods 274: 139-147. (Pubitemid 36263050)
24. Yang OO, Kalams SA, Trocha A, Cao H, Luster A, et al (1997) Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 71: 3120-3128. (Pubitemid 27119959)
25. Tartaglia J, Excler JL, El HR, Limbach K, Meignier B, et al (1998) Canarypox virus-based vaccines: prime-boost strategies to induce cell-mediated and humoral immunity against HIV. AIDS Res Hum Retroviruses 14 Suppl 3: S291-S298.
26. Papagno L, Alter G, Assoumou L, Murphy RL, Garcia F, et al (2011) Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25: 27-36. 10.1097/QAD.0b013e328340fe55 [doi].
27. Clements-Mann ML, Weinhold K, Matthews TJ, Graham BS, Gorse GJ, et al (1998) Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 177: 1230-1246. (Pubitemid 28194262)
28. Lin SW, Cun AS, Harris-McCoy K, Ertl HC (2007) Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine 25: 2187-2193. S0264-410X(06)01253-9 [pii];10.1016/j.vaccine.2006.11.044 [doi].
29. Pal R, Venzon D, Santra S, Kalyanaraman VS, Montefiori DC, et al (2006) Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 80: 3732-3742. 80/8/3732 [pii];10.1128/JVI.80.8.3732-3742.2006 [doi].